Enhancing connections in the central nervous system.

Cannabinoids interact with specific receptors and pathways implicated in a range of diseases throughout the body to produce pharmacologic effects. These include potential inhibition and modulation of several pathways resulting in a cumulative anti-convulsive effect, and the modulation of the endocannabinoid system, which regulates emotional responses, behavioral reactivity to context, and social interaction. There are three types of cannabinoids: phytocannabinoids, or plant-derived and found in the Cannabis plant; endocannabinoids, or cannabinoids the body produces to control certain biochemical pathways; and synthetic cannabinoids, or those pharmaceutically manufactured to be structurally and functionally identical to phyto- and endocannabinoids. The two most researched cannabinoids are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).  Despite their similar chemical structures, CBD is a compound that doesn’t produce the euphoric effects or “high” associated with THC and Cannabis.

At Zynerba, we focus our current development efforts on CBD as it has demonstrated positive effects in the CNS and is non-euphoric and non-addictive.